Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (23): 4359-4362.doi: 10.3969/j.issn.1673-8225.2011.23.041

Previous Articles     Next Articles

Safety and efficacy of cord blood mononuclear cells and umbilical cord mesenchymal stem cells therapy for childhood autism

Liu Min1, Lü Yong-tao2, Huan Ying2, Ge Ru-cun3, Zhang Jun4, Jiang Shu4, Guo Chuan-qin5, Hu Xiang4, Chen Xing-wang2, Luo Zhao-xia4, An Lei4   

  1. 1Department of Rehabilitation Medicine, Shandong Jiaotong Hospital, Jinan  250031, Shandong Province, China; 2Department of Neurology, Shandong Jiaotong Hospital, Jinan  250031, Shandong Province, China; 3Cell Rescue Center of Shandong Jiaotong Hospital, Jinan  250031, Shandong Province, China; 4Shenzhen Beike Cell Engineering Research Institute, Shenzhen  518057, Guangdong Province, China; 5Shandong Mental Health Center, Jinan  250014, Shandong Province, China
  • Received:2011-03-14 Revised:2011-04-24 Online:2011-06-04 Published:2011-06-04
  • About author:Liu Min★, Master, Associate chief physician, Department of Rehabilitation Medicine, Shandong Jiaotong Hospital, Jinan 250031, Shandong Province, China lm-jtyy@163.com
  • Supported by:

    Beijing Wuzuze Science and Technology Development Foundation*; a grant from Communication Department of Shandong Province, No. 2009Z41-4*

PDF

399

Abstract:

BACKGROUND: There is no clear standard for curing autism, and the effect of rehabilitation treatment is not satisfied.
OBJECTIVE: To evaluate the safety and efficacy of cord blood mononuclear cells (MNCs) and umbilical cord mesenchymal stem cells (MSCs) in treating autistic children.
METHODS: Thirty-seven children with autism were divided into MNCs treatment (MNCs plus rehabilitation treatment), MNCs combined with MSCs treatment (MNCs combined with MSCs plus rehabilitation treatment) and control (rehabilitation treatment alone) groups. Related laboratory examinations were performed for each group before treatment, 1, 2 and 6 months after treatment to observe adverse effects. Childhood Autism Rating Scale and Aberrant Behavior Checklist were employed to assess the children of autism.
RESULTS AND CONCLUSION: There was no statistical difference between MNCs treatment group and MNCs combined with MSCs treatment group in laboratory examinations at each time point, and no adverse effects were observed in two groups. Childhood Autism Rating Scale and Aberrant Behavior Checklist showed that three treatment presented efficacy, but the MNCs combined with MSCs treatment group was the best, followed by MNCs treatment group, and then control group.

CLC Number: